AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01000870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNI-513-01
Description: Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
Study NCT00772928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
Description: 0.5 mL, Intramuscular
Study NCT03730298 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American Ginseng
Description: cpr
Study NCT03730298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cpr
Study NCT01192087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface cetuximab weekly doses (from RT treatment start throughout radiation treatment): 250 mg/m² body surface
Study NCT02734368 — intervention group
Intervention type: DRUG
Intervention: Hyperpolarized Helium-3
Study NCT02264392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Incision and Drainage
Description: Ultrasound guidance of the abscess drainage
Study NCT02264392 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blind Incision and Drainage
Description: Incision and drainage of abscess guided by physical exam alone
Study NCT01019356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4 mg twice daily for 8 weeks orally
Study NCT01019356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: 100 mg three times daily for 8 weeks orally
Study NCT03233165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Ablation of the lesions Device: Er:YAG laser (LightWalker AT, Fotona, Slovenia, 2013) with a non-contact X-Runner digitally controled hand-piece.~Settings for the Er:YAG laser were as follows: pulse mode was Quantum Square Pulse (QSP), pulse energy of 120mJ, frequency of 20Hz and water sprey level was set to10ml per minute.
Study NCT04190446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04190446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04190446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02510274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3325
Description: oral
Study NCT03266653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytotoxic t-lymphocytes
Description: EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
Study NCT03233165 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser
Description: Ablation of the lesions Device: Er,Cr:YSGG laser(WaterLase iPlus, Biolase LTD, USA) using contact mode. Settings were subsequent: power 50W, frequency 50Hz and concentration ratio of air and water was 2:4.
Study NCT00811187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine paracervical block
Description: 5cc 1% lidocaine injection in each paracervical region
Study NCT00811187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 5cc Normal Saline injection in each paracervical region
Study NCT05391204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional Tests
Description: Various physical exercices of inferior members
Study NCT05391204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Tests
Description: Various physical exercices of inferior members
Study NCT03791177 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Music Therapy
Description: Patients in the study group were exposed to flute music therapy (Sufi musical recital - Huseyni mode) at low tempo (60-80 rhythm / min) with weak beats and calm rhythms during the UDS.~This audition involves both vocal and instrumental music performed by a reed flute called 'Ney'. A competent lecturer who was specialized in music suggested all the musical compositions during the therapy
Study NCT03791177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patients in the study group were exposed to flute music therapy (Sufi musical recital - Huseyni mode) at low tempo (60-80 rhythm / min) with weak beats and calm rhythms during the UDS.~This audition involves both vocal and instrumental music performed by a reed flute called 'Ney'. A competent lecturer who was specialized in music suggested all the musical compositions during the therapy
Study NCT01127776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APOS SYSTEM
Description: The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units
Study NCT01127776 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: APOS SYSTEM without biomechanics units.
Description: The control group will receive the same walking protocol as the trial group without biomechanics units
Study NCT03184649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: It is a pre-analgesic will be taken before painful procedures.
Study NCT03184649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: it is a pre-analgesic drug will be taken before painful procedure.
Study NCT01134809 — intervention group
Intervention type: PROCEDURE
Intervention: Major abdominal surgery
Description: All adult patients having major abdominal surgery
Study NCT03766828 — intervention group
Intervention type: PROCEDURE
Intervention: inside-out-access technique with inside-out access device (Surfacer (R))
Description: inside-out-access technique with (Surfacer (R)) with a new CE certified device (Surfacer (R), Bluegrass Vascular)
Study NCT03766828 — intervention group
Intervention type: PROCEDURE
Intervention: access technique including Sharp recanalization
Description: access technique with Sharp recanalization via interventional radiology
Study NCT01607970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
Study NCT01607970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
Study NCT01697787 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amodiaquine-Artesunate
Description: If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
Study NCT01697787 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Artemether-lumefantrine
Description: If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
Study NCT00184028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
Study NCT00184028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.
Study NCT03232190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web Application
Description: Parents receive a web application that offers information and support until the age of 2.
Study NCT04317170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants will be played Frederic Chopin's piano sonatas through a headphone device prior to and during injection of local anesthesia during their routine standard of care dermatologic procedure
Study NCT00812630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MENT or placebo
Description: A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
Study NCT01447797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0912 / Irbesartan and Atorvastatin
Description: Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
Study NCT01447797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCP0912 / Irbesartan and Atorvastatin
Description: Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
Study NCT04612309 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: patient treated with at least 1 immunotherapy administration
Study NCT01167023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally, once daily for 30 days.
Study NCT01167023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily for 30 days.
Study NCT02747264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eRAPID
Description: eRAPID is an online system for patients to self-report symptoms and AE during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
Study NCT01253200 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blazer® Open-Irrigated Ablation Catheter
Description: Blazer® Open-Irrigated Ablation Catheter
Study NCT01253200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Catheter
Description: Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
Study NCT00910884 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: No supplements are given
Study NCT00910884 — intervention group
Intervention type: PROCEDURE
Intervention: therapeutic dietary intervention
Description: Given orally daily for 12 months
Study NCT01506921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic ketamine
Description: 0.6 mg/kg
Study NCT01506921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-ketamine
Description: 0.3 mg/kg
Study NCT03423901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Descriptive analysis of clinical, biological and histological of 3 arms: ABO incompatible, HLA incompatible, and ABO/HLA incompatible kidney transplantation (1 and 5 years posttransplantation in each groups)
Study NCT02605499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UV-C light disinfection
Description: UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
Study NCT01700530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Statins (40mg/day)for 12 weeks
Study NCT01700530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise only
Description: 12 weeks of exercise training (5 days a week for 45-50 min a session)
Study NCT01700530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Statins + Exercise
Description: Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
Study NCT01630083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin
Description: Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.
Study NCT02253238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Survey
Description: Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
Study NCT02253238 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality of Life Survey
Description: Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
Study NCT02253238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Management Surveys
Description: Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
Study NCT02391623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
Study NCT02821910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted
Description: High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
Study NCT02821910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed
Description: Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
Study NCT03026088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: Participants received Bisoprolol orally, once daily at a dose of 1.25 milligram (mg) up to Weeks 3, and then it was up-titrated to 2.5 mg up to Week 6, 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18 and 10 mg up to Week 26.
Study NCT02253238 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Management Surveys
Description: Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
Study NCT02253238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring Devices
Description: Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer)
Study NCT01630083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: Epirubicin will be administered at a dose of 50 mg/m\^2 as a 15-minute intravenous infusion on day 1 of each cycle.
Study NCT01630083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.
Study NCT01630083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Oxaliplatin will be administered at a dose of 130 mg/m\^2 as a 2-hour intravenous infusion on day 1 of each cycle.
Study NCT01630083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
Study NCT01630083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: The daily dose of capecitabine will be 1250 mg/m\^2. Capecitabine tablets to be given once daily at a dose of 625 mg/m\^2 orally in the evening of day 1 of each cycle and twice daily at a dose of 625 mg/m\^2 orally on days 2 to 21 of each cycle; the morning dose of capecitabine on day 1 of each cycle to be omitted due to administration of zolbetuximab, epirubicin and oxaliplatin.
Study NCT01278303 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment of Aortic Wall Injury
Description: A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
Study NCT01020539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning Regimen
Study NCT03184649 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: A fruit-flavored orange color placebo solution
Description: orange juice as a comparative group.
Study NCT03492476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circaid
Description: Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of the circaid® compression system~* Day of Discharge (DD) from the hospital to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime compression system circaid®~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with the nighttime circaid® compression system
Study NCT03492476 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short-stretching Bandage (Reference treatment)
Description: Three observation periods were defined with the following products:~* D1 to D5: intensive hospital treatment performed by the night and day wearing of short stretching tapes.~* DD (Day of discharge from the hospital) to DD +30: ambulatory initial maintenance phase carried out by the wearing of a compression sleeve on the day associated with a possible treatment at night, as recommended by HAS.~* DD + 31 to DD + 90: ambulatory maintenance phase carried out by the wearing of a compression sleeve on the day associated with possible treatment at night
Study NCT01020539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Conditioning Regimen
Study NCT01630083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Two different formats of zolbetuximab, comprising different strengths, to be provided. Vials contained 22 mg or 105 mg of zolbetuximab. Prior to administration, zolbetuximab will be reconstituted with 1.1 mL (22 mg zolbetuximab vials) or 5.0 mL (105 mg zolbetuximab vials) water for injection, which will result in a concentration of 20 mg/mL zolbetuximab. The extractable volume per vial will be 1 mL (for 22 mg zolbetuximab vials) or 5 mL (for 105 mg zolbetuximab vials). The reconstituted solution will be further diluted with sodium chloride 0.9% to a final concentration of 2 mg/mL zolbetuximab. Zolbetuximab will be administered as an intravenous infusion over 2 to 3 hours.
Study NCT04572243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to lorcaserin oral tablet, administered as oral suspension.
Study NCT04572243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: Lorcaserin oral tablet, administered as oral suspension.
Study NCT04572243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorcaserin
Description: Lorcaserin oral tablet, administered as oral suspension.
Study NCT01635530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline: 100mg tablet two times per day, four weeks
Study NCT01635530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: 2 g intravenous once a day, three weeks
Study NCT03381586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Subjects randomized to Group A (n=8) will receive ALT-803 at a concentration of 1.0 mg/mL and subjects randomized to Group B (n=8) will receive ALT-803 at a concentration of 2.0 mg/mL. Subjects will receive a single 10 µg/kg subQ dose of ALT-803 on Day 1 of study period 1. After a rest period, subjects will receive a single 20 µg/kg subQ dose of ALT-803 on Day 1 of study period 2.
Study NCT00721955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Inhaled loxapine Placebo, may repeat after 2 hours x 2
Study NCT00721955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 5 mg
Description: Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
Study NCT00721955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled loxapine 10 mg
Description: Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
Study NCT03024268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Figulla Flex Occluder (Occlutech)
Description: Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
Study NCT02339038 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ledipasvir 90 mg and Sofosbuvir 400 mg
Description: Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
Study NCT03646162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veru-944
Description: Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT
Study NCT03646162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo